Alan Whitters, MD
Psychiatry · Cedar Rapids, IANPI 1093778532
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $144,938 of the $169,512 with a category attached, or 85.5%. 14 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 41.4% of the total. Among psychiatry clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $519.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$70K
- Otsuka America Pharmaceutical, Inc.$49K
- Alkermes, Inc.$28K
- E.r. Squibb & Sons, L.L.C.$21K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$266
- Neurocrine Biosciences, Inc.$190
- plus $423 from 8 others
What the payments were for
- Consulting fees$4600%
- Speaking & faculty fees$144,93886%
- Travel & lodging$16,45110%
- Food & beverage$7,5864%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 101 | $70,117 |
| Otsuka America Pharmaceutical, Inc. | 86 | $48,887 |
| Alkermes, Inc. | 52 | $28,488 |
| E.r. Squibb & Sons, L.L.C. | 49 | $21,141 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $266 |
| Neurocrine Biosciences, Inc. | 6 | $190 |
| Johnson & Johnson | 13 | $162 |
| AbbVie(2 entities) | 5 | $99 |
| Lundbeck LLC | 2 | $48 |
| Sunovion Pharmaceuticals Inc. | 3 | $43 |
| Shire North American Group Inc | 2 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$109,134
- ABILIFY MAINTENA$47,221
- AUSTEDO$34,247
- Austedo XR$33,437
- COBENFY$19,327
- ABILIFY ASIMTUFII$4,161
- REXULTI$264
How this compares
$169,512 in reported general payments places this provider in the 95th percentile of 245 psychiatry providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 60 | $411,526 |
| Invega SustennaPaliperidone Palmitate | 102 | $318,412 |
| Abilify MaintenaAripiprazole | 14 | $40,793 |
| Risperdal ConstaRisperidone Microspheres | 14 | $35,963 |
| VraylarCariprazine Hcl | 21 | $27,407 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $26,595 |
| Clozapine | 293 | $23,680 |
| Aripiprazole | 83 | $17,296 |
| TrulicityDulaglutide | 11 | $11,248 |
| Fluphenazine Hcl | 76 | $11,017 |
| Olanzapine | 416 | $7,870 |
| JardianceEmpagliflozin | 11 | $6,914 |
| Victoza 2-PakLiraglutide | 12 | $6,835 |
| Divalproex Sodium ErDivalproex Sodium | 89 | $5,934 |
| Perphenazine | 33 | $5,063 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $70,117 | $411,52660 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $162 | $354,374116 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $48,887 | $40,79314 claims |
| AbbVieVraylar | $99 | $27,40721 claims |
| Alkermes, Inc.Lybalvi | $28,488 | $26,59518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 245 psychiatry providers in Iowa.
Other psychiatry in Cedar Rapids
- Dwight SchroederCedar Rapids$13K
- Jacob MillerCedar Rapids$2K
- Jeffrey WilharmCedar Rapids$2K
- Allyson WheatonCedar Rapids$2K
- Rebecca WolfeCedar Rapids$1K
- Frank BabcockCedar Rapids$1K
- Sundara Rameshwar Munagala VenkataCedar Rapids$867
- Charles JennischUrbandale$949K
- Manmohan SinghDes Moines$408K
- Jimmy MascaroOttumwa$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.